Skip to content
Protocolos
Experimental reference

Peptides, nootropics and related compounds — in English, with the limits of the evidence in plain view.

29 pages with the figure verified by me in PubMed, the package insert and ClinicalTrials.gov — with the query declared in each one
57 pages with the dose carried over from a commercial secondary source and translated, without my having checked the figure at the origin

The difference between the two is printed on every table of this site: where the figure was verified, the table carries a ruler on its edge and the value is set in a different typeface. Where it was not, it carries nothing.

Experimental material. Read before using anything from here.

Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.

Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.

Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.

Nootropics

The site was born from peptides, but the most consulted part today is this one — and they are two different questions, on two pages. How many trials exist is not the same thing as what they found.

Nootropics32 with human evidence, 12 with no trial at all — and four counts that were inflated Effect sizeHow many trials exist is one question; what they found is another — 34 meta-analyses opened

O filtro é atalho, não porta. Os 87 compostos estão listados e linkados abaixo, agrupados por seção — dá para chegar em qualquer um rolando a página, sem buscar.

The registration badge comes from the scan of open data done on September 4, 2026, and appears only on the 44 compounds that were measured one by one. Combinations and method pages have no badge.

Repair and tissue

Compounds studied in wound healing, tendon, skin and local inflammation.

ARA-290 (cibinetide)

Not approved

EPO fragment without the effect on red blood cells

Repair and tissue4 table(s)

BPC-157

Not approved

The most discussed repair peptide — and almost only in animal models

Repair and tissue5 table(s)

Cartalax

Not approved

Short bioregulator studied in cartilage

Repair and tissue16 table(s)

GHK-Cu

Not approved

Copper peptide — accumulation is the variable that governs the cycle

Repair and tissue3 table(s)

KPV

Not approved

Anti-inflammatory tripeptide, fragment of α-MSH

Repair and tissue11 table(s)

LL-37

Not approved

The only human cathelicidin antimicrobial peptide

Repair and tissue3 table(s)

TB-500

Not approved

Fragment of thymosin beta-4 — cell migration

Repair and tissue5 table(s)

Metabolic and weight

Incretin agonists and related compounds studied in weight and glycemia.

5-Amino-1MQ

Not approved

Small molecule, not a peptide, studied in fat and NNMT

Metabolic and weight10 table(s)

AOD-9604

Not approved

GH fragment studied in lipolysis

Metabolic and weight10 table(s)

Cagrilintide

Not approved

Weekly amylin analog, under investigation

Metabolic and weight5 table(s)

Lipo-C

Partially approved

Compounded lipotropic injection — not a peptide

Metabolic and weight2 table(s)

Retatrutide

Not approved

Triple agonist in phase 3 — GIP, GLP-1 and glucagon

Metabolic and weight8 table(s)

SLU-PP-332

Not approved

Pan-ERR agonist sold as an 'exercise mimetic'

Metabolic and weight5 table(s)

Semaglutide

Approved

Ozempic, Wegovy and Rybelsus — the same molecule

Metabolic and weight9 table(s)

Survodutide

Not approved

Dual GLP-1/glucagon agonist, code BI 456906

Metabolic and weight3 table(s)

Tesofensine

Not approved

Triple reuptake inhibitor, as an oral tablet

Metabolic and weight2 table(s)

Tirzepatide

Approved

Dual GLP-1/GIP agonist — Mounjaro and Zepbound

Metabolic and weight4 table(s)

Growth hormone axis

GHRH analogs and secretagogues that ask the body itself to release GH.

CJC-1295 with DAC

Not approved

Long-acting GHRH analog, albumin-bound

Growth hormone axis5 table(s)

CJC-1295 without DAC (Mod GRF 1-29)

Not approved

Short GHRH pulse, no accumulation

Growth hormone axis4 table(s)

GHRP-6

Not approved

Secretagogue that mimics ghrelin — and opens up hunger along with it

Growth hormone axis2 table(s)

IGF-1 LR3

Not approved

Long-acting IGF-1 analog — the highest-risk one in the GH group

Growth hormone axis7 table(s)

Ipamorelin

Not approved

Selective secretagogue, without the hunger trigger of GHRP-6

Growth hormone axis10 table(s)

Sermorelin (GRF 1-29)

Partially approved

Copy of the first 29 amino acids of GHRH

Growth hormone axis2 table(s)

Tesamorelin

Approved

The only GHRH analog approved by the FDA

Growth hormone axis7 table(s)

Neuro and cognition

Compounds studied in attention, memory, anxiety and sleep.

Adamax

Not approved

Experimental relative of Semax, with almost no published research

Neuro and cognition4 table(s)

Methylene blue

Partially approved

An 1876 dye that became a hospital drug

Neuro and cognition1 table(s)

Cerebrolysin

Partially approved

Injectable mixture of porcine-derived peptides

Neuro and cognition1 table(s)

DSIP

Not approved

Delta sleep-inducing peptide — a name bigger than the evidence

Neuro and cognition4 table(s)

Pinealon (EDR)

Not approved

Short bioregulator from the Khavinson school

Neuro and cognition5 table(s)

Selank (TP-7)

Partially approved

Russian peptide anxiolytic, Semax's counterpart

Neuro and cognition10 table(s)

Semax

Partially approved

Russian heptapeptide derived from ACTH, linked to BDNF

Neuro and cognition4 table(s)

Longevity and mitochondria

Targets linked to senescence, NAD+ and mitochondrial function.

Epitalon (epithalon, AEDG)

Not approved

Russian tetrapeptide associated with telomerase

Longevity and mitochondria3 table(s)

FOXO4-DRI

Not approved

Experimental senolytic — the narrowest margin on this list

Longevity and mitochondria4 table(s)

Glutathione

Partially approved

The antioxidant the body already makes

Longevity and mitochondria1 table(s)

Humanin (HNG)

Not approved

Peptide encoded in the mitochondria, not in the nucleus

Longevity and mitochondria3 table(s)

MOTS-c

Not approved

Mitochondrial peptide linked to the AMPK pathway

Longevity and mitochondria5 table(s)

NAD+

Not approved

Central coenzyme — the route of administration changes everything

Longevity and mitochondria14 table(s)

SS-31 (elamipretide)

Not approved

Peptide that binds mitochondrial cardiolipin

Longevity and mitochondria4 table(s)

Hormonal and sexual

Reproductive axis, libido, pigmentation and vasodilation.

Kisspeptin

Not approved

The upstream switch of the reproductive axis

Hormonal and sexual6 table(s)

Melanotan II (MT-2)

Not approved

Tanning through the melanocortin pathway — and a list of effects

Hormonal and sexual5 table(s)

Oxytocin

Partially approved

Hormone approved in obstetrics, used off-label in social cognition

Hormonal and sexual4 table(s)

PT-141 (Bremelanotide)

Partially approved

MC3R/MC4R agonist — approved in the US as Vyleesi

Hormonal and sexual4 table(s)

VIP (vasoactive intestinal peptide)

Not approved

28-amino-acid neuropeptide, very short half-life

Hormonal and sexual4 table(s)

Immune

Modulation of the immune response.

Thymosin alpha-1 (TA1)

Partially approved

Immune modulator registered outside the US

Immune6 table(s)

Combinations

Protocols that combine two or more compounds in the same cycle.

Advanced Recomp

Not approved

Retatrutide + CJC-1295 without DAC + ipamorelin

Combinations8 table(s)

CJC-1295 without DAC + Ipamorelin

Not approved

The community's most carefully planned GH pair

Combinations6 table(s)

CagriSema

Not approved

Cagrilintide 2.4 mg + semaglutide 2.4 mg, fixed dose

Combinations6 table(s)

Cagrilintide + Retatrutide

Not approved

Triple agonist plus an amylin analog

Combinations8 table(s)

Cagrilintide + Tirzepatide

Not approved

Weekly appetite pair

Combinations5 table(s)

Russian nootropic pair

Not approved

Semax + Selank

Combinations6 table(s)

GLOW

Not approved

BPC-157 + TB-500 + GHK-Cu in one vial

Combinations8 table(s)

KLOW

Not approved

GHK-Cu + KPV + BPC-157 + TB-500, 80 mg vial

Combinations6 table(s)

Reta + MOTS-c

Not approved

Appetite through one pathway, mitochondria through another

Combinations5 table(s)

Tesamorelin + Ipamorelin

Not approved

Two different doors to the same GH pulse

Combinations3 table(s)

Wolverine

Not approved

BPC-157 + TB-500, the repair base

Combinations9 table(s)

Verified against primary sources

Pages built directly from PubMed and ClinicalTrials.gov, not from the secondary source. They carry the evidence count and the query used.

Dose adjustment for hepatic function

Partially approved

Here it is not just a gap: there is documented harm, with numbers and outcomes — and it hits exactly the people this site attracts

Verified against primary sources5 table(s)

Dose adjustment for renal function

Partially approved

Where the data exist, the package insert says not to adjust anything — and the real risk sits three sections up, in an item almost nobody reads

Verified against primary sources2 table(s)

Anticorpos monoclonais

Partially approved

Trinta e cinco vezes maior que um peptídeo, feito por célula viva e dado em infusão venosa — dos três que aparecem na conversa de composição corporal, um único tem bula

Verified against primary sources4 table(s)

Khavinson short bioregulators

Not approved

Eleven peptides, five clinical studies, zero registered trials

Verified against primary sources2 table(s)

CRISPR

Partially approved

Out of 64,641 articles, 67 are clinical trials and 1 became a drug — and what limits that drug is not the gene editing, it is the chemotherapy around it

Verified against primary sources11 table(s)

Calvície — o antigo e o que está chegando

Partially approved
Verified against primary sources3 table(s)

Casgevy

Partially approved

The declared bottleneck is not the price — in England there are 1,794 eligible patients and 23 treatments in the first year, and the reason the assessor writes down is hospitalization, not cost

Verified against primary sources9 table(s)

Kidney disease

Partially approved

From zero to six drugs in four and a half years — and five of them were approved on a number that is not the one that matters to the patient

Verified against primary sources5 table(s)

Exossomos

Not approved

45.674 artigos, 83 ensaios randomizados e nenhum produto aprovado em agência nenhuma

Verified against primary sources2 table(s)

Fígado e lipídio

Partially approved
Verified against primary sources3 table(s)

Geroprotetores

Partially approved
Verified against primary sources3 table(s)

Incretinas e amilinas de nova geração

Partially approved
Verified against primary sources3 table(s)

Prescription-only items from the list

Partially approved

13 drugs that appeared mixed in with supplements

Verified against primary sources2 table(s)

KLOW — the evidence

Not approved

The blend still has no trial, but three components entered clinical phase in 2026

Verified against primary sources2 table(s)

Mazdutide

Not approved

12 phase 3 trials, published in NEJM, JAMA and Nature — and no package insert

Verified against primary sources2 table(s)

Eastern European drugs

Partially approved

18 imported drugs, 29 registered trials — and a forgotten history of deaths

Verified against primary sources3 table(s)

Meldonium (mildronate)

Partially approved

357 articles, 7 registered trials — and a detection window of months

Verified against primary sources4 table(s)

Músculo, osso, eixo HPG e imune

Partially approved
Verified against primary sources3 table(s)

Neuro e cognição — o bloco russo e o que tem bula

Partially approved
Verified against primary sources3 table(s)

Nootropics

Partially approved

32 with human evidence, 12 with no trial at all — and four counts that were inflated

Verified against primary sources3 table(s)

O eixo do GH fora do frasco de peptídeo

Partially approved
Verified against primary sources3 table(s)

The GLP-1s against the package insert

Partially approved

The doses were right. The black box warning was missing

Verified against primary sources6 table(s)

Reparo além do BPC e do TB-500

Not approved

A timosina β-4 tem 4 ensaios de fase 3 — e são de colírio para olho seco, não de reparo muscular; o AHK-Cu tem 1 artigo no PubMed

Verified against primary sources3 table(s)

SARMs

Not approved

Half of the products sold as SARMs do not contain the SARM on the label — and four of the most popular have never had a clinical trial

Verified against primary sources8 table(s)

Semax — the evidence

Partially approved

The dose in the Russian trials is 12 to 72 times the community's

Verified against primary sources2 table(s)

Effect size

Partially approved

How many trials exist is one question; what they found is another — 34 meta-analyses opened

Verified against primary sources3 table(s)

Thymalin

Partially approved

Russian thymic extract — 293 articles, 13 trials, zero trial registrations

Verified against primary sources2 table(s)

Tratamentos que não são substância

Partially approved

Cinco procedimentos que competem com os frascos deste site e somam 69.593 artigos no PubMed e 5.349 estudos registrados

Verified against primary sources2 table(s)

Alcohol and steatosis

Partially approved

The underlying cause no liver panel sees — and one that multiplies, rather than adds to, the risk of everything else you take

Verified against primary sources6 table(s)

Supplements and related compounds

Over-the-counter items, with the dose range used in studies. Kept separate from those that require a prescription.

Herbal medicines and nootropics

Not approved

18 items where marketing usually runs ahead of the data

Supplements and related compounds3 table(s)

Over-the-counter supplements

Partially approved

43 items with dose, from what has good evidence to what has only marketing

Supplements and related compounds5 table(s)